RemeGen Biosciences
Hang Chen has a strong background in the biotech industry with significant experience in various roles. Hang is currently serving as the Vice President and Head of Therapeutic Biology at RemeGen Biosciences, a position they have held since April 2021. Before joining RemeGen, they were the Head of Therapeutic Biology at the same company starting in October 2020.
Prior to RemeGen, Hang Chen served as the Vice President of Research at BridGene Biosciences, Inc. from October 2018 to October 2020. Hang also held the role of Leader of Glial Biology at Denali Therapeutics from June 2015 to April 2018.
Hang Chen's earlier career includes positions at Amgen, where they worked as a Principal Scientist from August 2004 to June 2015, Renovis as a Senior Scientist from August 2000 to August 2004, and UCSF as a PostDoc from November 1996 to August 2000. Hang also worked as a Scientist at NextStar from August 1995 to November 1996.
Hang Chen holds a Ph.D in Molecular, Cellular, Developmental Biology and Biochemistry from the University of Colorado Boulder.
This person is not in any offices
RemeGen Biosciences
1 followers
RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or best-in-class biotherapeutics with innovative target discovery strategies, advanced molecule design and protein engineering platforms. Our passion is to serve patients with more effective therapies in a timely manner.